Argo Biopharma Showcases Phase II Data for BW-20805 at AAAAI 2026

Argo Biopharmaceutical Co., Ltd. has been selected for a late-breaking abstract at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting, taking place February 27–March 2, 2026.

The presentation will feature Phase II interim data for BW-20805, an investigational siRNA therapy for Hereditary Angioedema (HAE).

Why BW-20805 Matters in HAE?

HAE is a rare, potentially life-threatening genetic condition marked by sudden swelling attacks. Many current therapies require frequent dosing, creating a strong need for long-acting preventive options.

BW-20805 targets prekallikrein (PKK), a well-validated HAE pathway, using RNA interference to suppress PKK production at the genetic level.

The goal: durable prevention of HAE attacks with infrequent dosing.

Late-Breaking Phase II Results

The open-label Phase II study, titled

“Significant HAE Attack Reduction with BW-20805, a Long-Acting Prophylactic Injection” (Poster ID: L42), delivered compelling interim data.

Key efficacy highlights

• 100% reduction in time-normalized HAE attack rate
  – 600 mg Q24W group
• 89% reduction
  – 300 mg Q24W group
• 87% reduction
  – 300 mg Q12W group
• 80% of patients (8/10) remained completely attack-free

Deep and Sustained PKK Suppression

BW-20805 demonstrated rapid and durable pharmacodynamic effects.

• 92% mean PKK reduction by Day 85 in pooled 300 mg groups
• ~97% PKK reduction in the 600 mg Q24W group
• Sustained suppression through Day 169, reaching 97–98% in long-term follow-up

These data support evaluation of a Q6M (every six months) dosing strategy.

Favorable Safety and Tolerability

BW-20805 was generally well tolerated across all dose levels.

• Mostly mild, transient injection-site reactions
• No serious adverse events reported

This safety profile strengthens its case as a long-acting prophylactic therapy.

Company Perspective

According to Dr. Dongxu Shu, Co-founder and CEO of Argo Biopharma, the late-breaking selection reflects the strength of the clinical data and supports further development of a potentially best-in-class prophylactic regimen for HAE patients.

About Argo Biopharma

Argo Biopharma is a clinical-stage biotechnology company developing next-generation RNAi therapeutics.

Its pipeline spans:

• Cardiovascular diseases
• Viral infections
• Metabolic disorders
• Rare and specialty diseases

The company currently has seven RNAi candidates in clinical development.

Bottom line: With near-complete attack suppression, deep PKK knockdown, and a clean safety profile, BW-20805 is positioning itself as a long-acting, potentially best-in-class prophylactic therapy for hereditary angioedema.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!